A metabolic perspective of peto’s paradox and cancer

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1673, 2015, Pages

  Dang, Chi V ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Body mass; Cancer metabolism; Metabolic rate; Oxidative stress; Peto s paradox

Indexed keywords

BODY MASS; BODY SIZE; CANCER; CELLS AND CELL COMPONENTS; GENOME; METABOLISM; MUTATION; OBSERVATIONAL METHOD; TUMOR;

ANIMALIA; MAMMALIA;

AGING; ANIMAL; BIOLOGICAL MODEL; BODY SIZE; CELL DIVISION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASMS; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

AGING; ANIMALS; BODY SIZE; CELL DIVISION; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTO-ONCOGENES;

EID: 84930890627     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0223     Document Type: Review

References (78)

1. Hanahan D, Weinberg RA. 2011 Hallmarks of cancer: the next generation. Cell 144, 646–674. (doi:10.1016/j.cell.2011.02.013).
2. Behjati S et al. 2014 Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature 513, 422–425. (doi:10.1038/nature13448).
3. Carlson CA, Kas A, Kirkwood R, Hays LE, Preston BD, Salipante SJ, Horwitz MS. 2012 Decoding cell lineage from acquired mutations using arbitrary deep sequencing. Nat. Methods 9, 78–80. (doi:10.1038/nmeth.1781).
4. Chapal-Ilani N, Maruvka YE, Spiro A, Reizel Y, Adar R, Shlush LI, Shapiro E. 2013 Comparing algorithms that reconstruct cell lineage trees utilizing information on microsatellite mutations. PLoS Comput. Biol. 9, e1003297. (doi:10.1371/journal.pcbi.1003297).
5. Zhou W, Tan Y, Anderson DJ, Crist EM, Ruohola-Baker H, Salipante SJ, Horwitz MS. 2013 Use of somatic mutations to quantify random contributions to mouse development. BMC Genomics 14, 39. (doi:10.1186/1471-2164-14-39).
6. Caulin AF, Maley CC. 2011 Peto’s paradox: evolution’s prescription for cancer prevention. Trends Ecol. Evol. 26, 175–182. (doi:10.1016/j.tree.2011.01.002).
7. Kelleher FC, O’Sullivan H. 2014 Oxford and the Savannah: can the hippo provide an explanation for Peto’s paradox? Clin. Cancer Res. 20, 557–564. (doi:10.1158/1078-0432.CCR-13-2010).
8. Nagy JD, Victor EM, Cropper JH. 2007 Why don’t all whales have cancer? A novel hypothesis resolving Peto’s paradox. Integr. Comp. Biol. 47, 317–328. (doi:10.1093/icb/icm062).
9. Roche B, Sprouffske K, Hbid H, Misse D, Thomas F. 2013 Peto’s paradox revisited: theoretical evolutionary dynamics of cancer in wild populations. Evol. Appl. 6, 109–116. (doi:10.1111/eva.12025).
10. Dang CV. 2012 Links between metabolism and cancer. Genes Dev. 26, 877–890. (doi:10.1101/gad.189365.112).
11. Schrodinger E. 1944 What is life? Cambridge, UK: Cambridge University Press.
12. Vander Heiden MG, Cantley LC, Thompson CB. 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033. (doi:10.1126/science.1160809).
13. Cantor JR, Sabatini DM. 2012 Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2, 881–898. (doi:10.1158/2159-8290.CD-12-0345).
14. Buttgereit F, Brand MD. 1995 A hierarchy of ATPconsuming processes in mammalian cells. Biochem. J. 312, 163–167.
15. Rolfe DF, Brown GC. 1997 Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol. Rev. 77, 731–758.
16. Berg J, Tymoczko JL, Stryer L. 2002 Biochemistry. New York, NY: W H Freeman.
17. Brand K. 1985 Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. Biochem. J. 228, 353–361.
18. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, Rabinowitz JD. 2013 Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 9, 712. (doi:10.1038/msb.2013.65).
19. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT. 2011 Glutamine: pleiotropic roles in tumor growth and stress resistance. J. Mol. Med. 89, 229–236. (doi:10.1007/s00109-011-0731-9).
20. Newsholme EA, Crabtree B, Ardawi MS. 1985 Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q. J. Exp. Physiol. 70, 473–489. (doi:10.1113/expphysiol.1985.sp002935).
21. Hensley CT, Wasti AT, DeBerardinis RJ. 2013 Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Investig. 123, 3678–3684. (doi:10.1172/JCI69600).
22. Laplante M, Sabatini DM. 2012 mTOR signaling in growth control and disease. Cell 149, 274–293. (doi:10.1016/j.cell.2012.03.017).
23. Dang CV. 2012 MYC on the path to cancer. Cell 149, 22–35. (doi:10.1016/j.cell.2012.03.003).
24. Damaghi M, Wojtkowiak JW, Gillies RJ. 2013 pH sensing and regulation in cancer. Front. Physiol. 4, 370. (doi:10.3389/fphys.2013.00370).
25. Parks SK, Chiche J, Pouyssegur J. 2013 Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13, 611–623. (doi:10.1038/nrc3579).
26. Chiche J, Brahimi-Horn MC, Pouyssegur J. 2010 Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 14, 771–794. (doi:10.1111/j.1582-4934.2009.00994.x).
27. Brahimi-Horn MC, Pouyssegur J. 2007 Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem. 43, 165–178. (doi:10.1042/BSE0430165).
28. Leinonen HM, Kansanen E, Polonen P, Heinaniemi M, Levonen AL. 2014 Role of the Keap1-Nrf2 pathway in cancer. Adv. Cancer Res. 122, 281–320. (doi:10.1016/B978-0-12-420117-0.00008-6).
29. Jaramillo MC, Zhang DD. 2013 The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179–2191. (doi:10.1101/gad.225680.113).
30. Brahimi-Horn MC, Chiche J, Pouyssegur J. 2007 Hypoxia and cancer. J. Mol. Med. 85, 1301–1307. (doi:10.1007/s00109-007-0281-3).
31. Semenza GL. 2012 Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207–214. (doi:10.1016/j.tips.2012.01.005).
32. Semenza GL. 2009 Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 19, 12–16. (doi:10.1016/j.semcancer. 2008.11.009).
33. Ackerman D, Simon MC. 2014 Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 24, 472–478. (doi:10.1016/j.tcb.2014.06.001).
34. Lane N. 2014 Bioenergetic constraints on the evolution of complex life. Cold Spring Harbor Perspect. Biol. 6, a015982. (doi:10.1101/cshperspect.a015982).
35. Lane N, Martin W. 2010 The energetics of genome complexity. Nature 467, 929–934. (doi:10.1038/nature09486).
36. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. 2003 A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer 3, 193–202. (doi:10.1038/nrc1013).
37. King A, Selak MA, Gottlieb E. 2006 Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25, 4675–4682. (doi:10.1038/sj.onc.1209594).
38. Cairns RA, Mak TW. 2013 Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 3, 730–741. (doi:10.1158/2159-8290.CD-13-0083).
39. Kohli RM, Zhang Y. 2013 TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472–479. (doi:10.1038/nature12750).
40. Teperino R, Schoonjans K, Auwerx J. 2010 Histone methyl transferases and demethylases: can they link metabolism and transcription? Cell Metab. 12, 321–327. (doi:10.1016/j.cmet.2010.09.004).
41. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. 2012 The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599–612. (doi:10.1038/nrc3343).
42. Coussens LM, Zitvogel L, Palucka AK. 2013 Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286–291. (doi:10.1126/science.1232227).
43. Louis P, Hold GL, Flint HJ. 2014 The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12, 661–672. (doi:10.1038/nrmicro3344).
44. Newman SJ, Smith SA. 2006 Marine mammal neoplasia: a review. Vet. Pathol. 43, 865–880. (doi:10.1354/vp.43-6-865).
45. Pompei F, Polkanov M, Wilson R. 2001 Age distribution of cancer in mice: the incidence turnover at old age. Toxicol. Ind. Health 17, 7–16. (doi:10.1191/0748233701th091oa).
46. Kleiber M. 1947 Body size and metabolic rate. Physiol. Rev. 27, 511–541.
47. Savage VM, Allen AP, Brown JH, Gillooly JF, Herman AB, Woodruff WH, West GB. 2007 Scaling of number, size, and metabolic rate of cells with body size in mammals. Proc. Natl Acad. Sci. USA 104, 4718–4723. (doi:10.1073/pnas.0611235104).
48. Schmidt-Nielsen K. 1970 Energy metabolism, body size, and problems of scaling. Fed. Proc. 29, 1524–1532.
49. West GB, Savage VM, Gillooly J, Enquist BJ, Woodruff WH, Brown JH. 2003 Physiology: why does metabolic rate scale with body size? Nature 421, 713; discussion 4. (doi:10.1038/421713a).
50. West GB, Brown JH, Enquist BJ. 2001 A general model for ontogenetic growth. Nature 413, 628–631. (doi:10.1038/35098076).
51. West GB, Brown JH, Enquist BJ. 1999 The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284, 1677–1679. (doi:10.1126/science.284.5420.1677).
52. West GB, Brown JH, Enquist BJ. 1997 A general model for the origin of allometric scaling laws in biology. Science 276, 122–126. (doi:10.1126/science.276.5309.122).
53. Kolokotrones T, Van S, Deeds EJ, Fontana W. 2010 Curvature in metabolic scaling. Nature 464, 753–756. (doi:10.1038/nature08920).
54. Kearney MR, White CR. 2012 Testing metabolic theories. Am. Nat. 180, 546–565. (doi:10.1086/667860).
55. Schmidt-Nielsen K, Pennycuik P. 1961 Capillary density in mammals in relation to body size and oxygen consumption. Am. J. Physiol. 200, 746–750.
56. Kayar SR et al. 1994 Capillary blood transit time in muscles in relation to body size and aerobic capacity. J. Exp. Biol. 194, 69–81.
57. Sousa T, Domingos T, Kooijman SA. 2008 From empirical patterns to theory: a formal metabolic theory of life. Phil. Trans. R. Soc. B 363, 2453–2464. (doi:10.1098/rstb.2007.2230).
58. Sousa T, Mota R, Domingos T, Kooijman SA. 2006 Thermodynamics of organisms in the context of dynamic energy budget theory. Phys. Rev. E Stat. Nonlinear Soft Matter Phys. 74, 051901. (doi:10.1103/PhysRevE.74.051901).
59. Maino JL, Kearney MR, Nisbet RM, Kooijman SA. 2014 Reconciling theories for metabolic scaling. J. Anim. Ecol. 83, 20–29. (doi:10.1111/1365-2656.12085).
60. Demetrius L. 2006 The origin of allometric scaling laws in biology. J. Theor. Biol. 243, 455–467. (doi:10.1016/j.jtbi.2006.05.031).
61. Demetrius L, Tuszynski JA. 2010 Quantum metabolism explains the allometric scaling of metabolic rates. J. R. Soc. Interface 7, 507–514. (doi:10.1098/rsif.2009.0310).
62. Porter RK, Brand MD. 1995 Causes of differences in respiration rate of hepatocytes from mammals of different body mass. Am. J. Physiol. 269, R1213–R1224.
63. Robb EL, Maddalena LA, Dunlop VA, Foster T, Stuart JA. 2012 Absence of metabolic rate allometry in an ex vivo model of mammalian skeletal muscle. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 162, 157–162. (doi:10.1016/j.cbpa.2012.01.022).
64. Brown MF, Gratton TP, Stuart JA. 2007 Metabolic rate does not scale with body mass in cultured mammalian cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R2115–R2121. (doi:10.1152/ajpregu.00568.2006).
65. Emmett B, Hochachka PW. 1981 Scaling of oxidative and glycolytic enzymes in mammals. Respir. Physiol. 45, 261–272. (doi:10.1016/0034-5687(81)90010-4).
66. Siegel JM. 2005 Clues to the functions of mammalian sleep. Nature 437, 1264–1271. (doi:10.1038/nature04285).
67. Eiland MM, Ramanathan L, Gulyani S, Gilliland M, Bergmann BM, Rechtschaffen A, Siegel JM. 2002 Increases in amino-cupric-silver staining of the supraoptic nucleus after sleep deprivation. Brain Res. 945, 1–8. (doi:10.1016/S0006-8993(02)02448-4).
68. Everson CA, Laatsch CD, Hogg N. 2005 Antioxidant defense responses to sleep loss and sleep recovery. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R374–R383. (doi:10.1152/ajpregu.00565.2004).
69. Xie L et al. 2013 Sleep drives metabolite clearance from the adult brain. Science 342, 373–377. (doi:10.1126/science.1241224).
70. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. 2014 Effect of 1 night of total sleep deprivation on cerebrospinal fluid beta-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 71, 971–977. (doi:10.1001/jamaneurol.2014.1173).
71. Herman AB, Savage VM, West GB. 2011 A quantitative theory of solid tumor growth, metabolic rate and vascularization. PLoS ONE 6, e22973. (doi:10.1371/journal.pone.0022973).
72. Meynet O, Ricci JE. 2014 Caloric restriction and cancer: molecular mechanisms and clinical implications. Trends Mol. Med. 20, 419–427. (doi:10.1016/j.molmed.2014.05.001).
73. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. 2010 Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 31, 83–89. (doi:10.1093/carcin/bgp280).
74. Wu JJ et al. 2013 Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep. 4, 913–920. (doi:10.1016/j.celrep.2013.07.030).
75. Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. 2014 Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol. Ther. 15, 586–592. (doi:10.4161/cbt.28164).
76. Anisimov VN et al. 2011 Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10, 4230–4236. (doi:10.4161/cc.10.24.18486).
77. Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S. 2013 Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multifaceted effects. Oncogene 32, 1475–1487. (doi:10.1038/onc.2012.181).
78. Pollak M. 2013 Potential applications for biguanides in oncology. J. Clin. Investig. 123, 3693–3700. (doi:10.1172/JCI67232).